 |
|
|
| |
SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA)
|
| |
| |
IAS 2021 July 18-22
Josep M. Llibre,1 Carlos Alves Brites,2 Chien-Yu Cheng,3,4 Olayemi Osiyemi,5 Carlos Galera,6
Laurent Hocqueloux,7 Franco Maggiolo,8 Olaf Degen,9 Libby Blair,10 Brian Wynne,10 James Oyee,11 Mark Underwood,10 Lloyd Curtis,11 Gilda Bontempo,10 Jean van Wyk12
1Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 2Universidade Federal da Bahia, Salvador, Brazil; 3Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; 4School of Public Health, National Yang-Ming University, Taipei, Taiwan; 5Triple O Research Institute PA, West Palm Beach, FL, USA; 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; 7Centre Hospitalier Régional d’Orléans, Orléans, France; 8ASST Papa Giovanni XXIII, Bergamo, Italy; 9Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11GlaxoSmithKline, Uxbridge, UK;
12ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
